Dr. Qixun Chen 陈奇勋
Chief Physician
Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of thoracic tumors and gastric cancer, including esophageal, lung, and stomach cancers. Focuses on minimally invasive techniques for radical resection with reduced trauma.
Dr. Chen is Chief Physician and Deputy Director of Thoracic Surgery at Zhejiang Cancer Hospital. Graduated from Zhejiang University School of Medicine in 1986, with training at the University of Arizona Cancer Center in 1992. Performs over 400 major thoracic surgeries annually. Completed three provincial research projects and published 11 papers.
Professional roles
- Member, Thoracic and Cardiovascular Surgery Branch, Zhejiang Medical Association
- Member, Esophageal Cancer Professional Committee, Zhejiang Anti-Cancer Association
- Member, Lung Cancer Professional Committee, Zhejiang Anti-Cancer Association
- Deputy Director and Secretary, Zhejiang Working Department, Thoracic Surgery Branch, Chinese Medical Doctor Association
Name order: in Chinese the family name comes first (Chen Qixun). Papers usually list the name as Qixun Chen or Chen Q.
Selected publications
105 papers on PubMed matched by name and affiliation; 22 as first or senior author since 2016. Most recent first- or senior-author papers:
- JTCVS Tech, 2026 (senior author): Inflatable mediastinoscopic esophagectomy for refractory benign esophageal fistulas: An effective therapeutical methods. PubMed 42891235
- Int J Radiat Oncol Biol Phys, 2026 (senior author): Randomized Study on Different Radiation Doses in Neoadjuvant Chemoradiation Therapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma (Neo-DRATEC Trial). PubMed 41713514
- Front Immunol, 2026 (senior author): Genomic alterations and dynamic molecular residual disease monitoring predict pathological response to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma. PubMed 42148099
- Front Immunol, 2025 (senior author): Serum creatinine to cystatin C ratio is a prognostic indicator in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy. PubMed 41041331
- Front Immunol, 2025 (senior author): Pretreatment immune-inflammatory prognostic score in predicting clinical outcomes in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy. PubMed 40842988
- Front Immunol, 2025 (senior author): The systemic oxidative stress index predicts clinical outcomes of esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy. PubMed 39958338
- Sci Rep, 2024 (senior author): Preoperative inflammatory burden index for prognostication in esophageal squamous cell carcinoma undergoing radical resection. PubMed 39730559
- Front Immunol, 2024 (senior author): Adjuvant immunotherapy after neoadjuvant immunochemotherapy and esophagectomy for esophageal squamous cell carcinoma: a real-world study. PubMed 39742260
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion